Match tier
Institution-verified
Presence
Current · Arkansas
Last published
2026
Sources
Institutional record
Refreshed
2026-10-05
O
Omar Atiq
Sourced from institutional research profiles (UAMS TRI or ARA).
PhD
Also affiliated: NXP (Netherlands) (2024); Dutch Polymer Institute (2022–2023); University of Bologna (2022–2026)
4 h-index
11 pubs
94 cited
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Omar Atiq's research has focused on two primary areas: the study of gas transport and solubility in semi-crystalline polymers, and clinical trials for therapeutic vaccines targeting head and neck cancer recurrence. In polymer science, Atiq has investigated hydrogen sorption and permeation in high-performance polyamides, and the impact of molecular structure on hydrogen sorption in polyethylene. His work also includes multi-scale modeling of gas solubility and analysis of gas transport properties in polyoxymethylene copolymers for potential barrier applications. Concurrently, Atiq has been involved in clinical research for a human papillomavirus therapeutic vaccine, PepCan, in phase I/II trials aimed at reducing recurrence in head and neck squamous cell carcinoma. He has published on these topics, with his most recent work dating to 2026. Atiq's scholarly output includes 11 publications and an h-index of 4, with collaborators including Keanna Marsh, Mindy Wilman, David W. Ussery, and Michael Scott Robeson from the University of Arkansas for Medical Sciences.
Metrics
- h-index: 4
- Publications: 11
- Citations: 94
Positions
-
PhD publications 2026University of Arkansas for Medical Sciences Institutional directory
-
PhD publications 2022–2026University of Bologna Department of Civil, Chemical, Environmental and Materials Engineering ORCID
Selected Publications
-
A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence (2026)
-
A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence (2026)
Grants & Funding
As listed on this researcher's institutional profile.
- Understanding and Enhancing T-Cell Responses to High Risk Human Papillomaviruses-Renewal NIH
- A Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab versus Relatlimab and Nivolumab in Participants with Unresectable or Metastatic Melanoma Regeneron Pharmaceuticals
- A Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab versus Relatlimab and Nivolumab in Participants with Unresectable or Metastatic Melanoma ICON Clinical Research via Regeneron Pharmaceuticals
Collaboration Network
Top Collaborators
Milan Bimali
University of Arkansas for Medical Sciences
2 shared publications
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
- A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence
Jasmine Crane
University of Arkansas for Medical Sciences
2 shared publications
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
- A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence
Nadia Darwish
University of Arkansas for Medical Sciences
2 shared publications
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
- A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence
Jennifer L. Faulkner
Winthrop Rockefeller Foundation
2 shared publications
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
- A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence
Rangaswamy Govindarajan
University of Arkansas for Medical Sciences
2 shared publications
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
- A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence
Alongkorn Kurilung
University of Arkansas for Medical Sciences
2 shared publications
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
- A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence
Keanna Marsh
University of Arkansas for Medical Sciences
2 shared publications
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
- A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence
Intawat Nookaew
University of Arkansas for Medical Sciences
2 shared publications
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
- A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence
Michael Robeson
University of Arkansas for Medical Sciences
2 shared publications
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
- A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence
Jumin Sunde
University of Arkansas for Medical Sciences
2 shared publications
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
- A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence
Mindy Wilman
Winthrop Rockefeller Foundation
2 shared publications
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
- A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence
Emily Ward Bivens
University of Arkansas for Medical Sciences
1 shared publication
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Teresa Evans
University of Arkansas for Medical Sciences
1 shared publication
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Ginger Brown
Winthrop Rockefeller Foundation
1 shared publication
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Aaron Johnson
Winthrop Rockefeller Foundation
1 shared publication
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Similar Researchers
Based on overlapping research topics
Emily Ward Bivens
University of Arkansas for Medical Sciences
Head and Neck Cancer Studies
Cancer Treatment and Pharmacology
Vaccine Coverage and Hesitancy
Teresa T. Evans
University of Arkansas for Medical Sciences
Head and Neck Cancer Studies
Cancer Treatment and Pharmacology
Vaccine Coverage and Hesitancy
Keanna Marsh
University of Arkansas for Medical Sciences
Head and Neck Cancer Studies
Cancer Treatment and Pharmacology
Clinical Research Studies
Jennifer L. Faulkner
University of Arkansas for Medical Sciences
Head and Neck Cancer Studies
Cancer Treatment and Pharmacology
Vaccine Coverage and Hesitancy
Kevin Wayne Lyon
University of Arkansas at Fayetteville
Molecular Dynamics Simulation
Materials Science Research
Raymond Weldon
University of Arkansas at Fayetteville
Molecular Dynamics Simulation
Materials Science Research